IDH2 and neoplasm: Tumor-derived IDH mutations disrupt their normal catalytic activity that converts isocitrate to α-ketoglutarate (α-KG) to a remarkable neomorphic activity that converts α-KG to D-2-hydroxyglutarate (D-2-HG), now referred to as an oncometabolite (82).